Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope
- PMID: 38058676
- PMCID: PMC10695902
- DOI: 10.1093/rap/rkad093
Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope
Abstract
The objective of this guideline is to provide up-to-date, evidence-based recommendations for the management of SLE that builds upon the existing treatment guideline for adults living with SLE published in 2017. This will incorporate advances in the assessment, diagnosis, monitoring, non-pharmacological and pharmacological management of SLE. General approaches to management as well as organ-specific treatment, including lupus nephritis and cutaneous lupus, will be covered. This will be the first guideline in SLE using a whole life course approach from childhood through adolescence and adulthood. The guideline will be developed with people with SLE as an important target audience in addition to healthcare professionals. It will include guidance related to emerging approved therapies and account for National Institute for Health and Care Excellence Technology Appraisals, National Health Service England clinical commissioning policies and national guidance relevant to SLE. The guideline will be developed using the methods and rigorous processes outlined in 'Creating Clinical Guidelines: Our Protocol' by the British Society for Rheumatology.
Keywords: biologic DMARDs; guideline; lupus nephritis; management; systemic lupus erythematosus.
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.
References
-
- Gordon C, Amissah-Arthur MB, Gayed M. et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018;57:e1–45. - PubMed
-
- Fanouriakis A, Kostopoulou M, Cheema K. et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713–23. - PubMed
-
- Rovin BH, Teng YKO, Ginzler EM. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021;397:2070–80. - PubMed
-
- Furie R, Rovin BH, Houssiau F. et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020;383:1117–28. - PubMed
-
- Palmer SC, Tunnicliffe DJ, Singh-Grewal D. et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis 2017;70:324–36. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources